Eleven Biotherapeutics Company Profile (NASDAQ:EBIO)

Analyst Ratings

Consensus Ratings for Eleven Biotherapeutics (NASDAQ:EBIO) (?)
Ratings Breakdown: 2 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $8.35 (210.41% upside)

Analysts' Ratings History for Eleven Biotherapeutics (NASDAQ:EBIO)
Show:
DateFirmActionRatingPrice TargetActions
1/19/2016Citigroup Inc.DowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/18/2016Leerink SwannDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Eleven Biotherapeutics (NASDAQ:EBIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
3/24/2016Q4($0.32)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.33)($0.50)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.43)($0.36)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115($0.57)($0.36)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015Q414($0.33)($0.49)$375.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q314($0.44)($0.66)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014($0.47)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eleven Biotherapeutics (NASDAQ:EBIO)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Eleven Biotherapeutics (NASDAQ:EBIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Eleven Biotherapeutics (NASDAQ:EBIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/27/2016Abbie CelnikerCEOSell10,029$2.08$20,860.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2016Karen L TubridyInsiderSell4,372$2.08$9,093.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2016Boxer Capital, LlcMajor ShareholderSell1,042,000$2.74$2,855,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016John J MccabeSVPSell1,501$0.27$405.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Abbie CelnikerCEOSell10,155$2.85$28,941.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Eric Steven FurfineInsiderSell4,652$2.85$13,258.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2015Jafco Super V3 Investment LimiMajor ShareholderSell33,400$13.23$441,882.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Jafco Super V3 Investment LimiMajor ShareholderSell17,900$11.62$207,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2015Jafco Super V3 Investment LimiMajor ShareholderSell120,000$11.62$1,394,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.85$74,655.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.82$74,466.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,100$12.07$73,627.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.54$23,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Jafco Super V3 Investment LimiMajor ShareholderSell1,165$11.54$13,444.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,600$11.81$30,706.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.75$23,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2014Jafco Super V3 Investment LimiMajor ShareholderBuy219,790$10.00$2,197,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Eleven Biotherapeutics (NASDAQ:EBIO)
DateHeadline
07/21/16 03:54 PMStocks Movements to Focus: Abbott Laboratories (NYSE:ABT) , Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Street Updates
07/21/16 03:54 PMStock Performance to Track: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - News Oracle
07/21/16 07:12 AMCould Eleven Biotherapeutics Inc See a Reversal After This Very Strong Session? - Consumer Eagle
07/21/16 07:12 AMEleven Biotherapeutics Inc. (EBIO) Jumps 8.13% on July 20 - Equities.com
07/19/16 03:49 PMEleven Biotherapeutics Inc (NASDAQ:EBIO)'s Company Shares Decreased 10.12% After Low Volatility - Consumer Eagle
07/19/16 03:49 PMEleven Biotherapeutics Inc. (EBIO) Jumps 9.52% on July 18 - Equities.com
07/15/16 10:55 AMEleven Biotherapeutics Inc. (EBIO) Drops 6.35% on July 13 - Equities.com
07/13/16 09:01 PMCould Eleven Biotherapeutics Inc Recover After Today's Huge Decline? - Consumer Eagle
07/13/16 07:40 AMEleven Biotherapeutics (NASDAQ:EBIO) Sentiment Report - Consumer Eagle
07/11/16 03:45 PMPre Session Movers- NVIDIA (NASDAQ:NVDA), Eleven Biotherapeutics (NASDAQ:EBIO), MSC Industrial Direct (NYSE ... - Seneca Globe
07/11/16 03:45 PMHC Stocks Broker Alerts: Pfizer Inc. (PFE), Eleven Biotherapeutics Inc (EBIO) - share market updates (press release)
07/11/16 03:45 PMTrending Stock Analysis: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - News Oracle
07/11/16 12:06 PMMovers And Shakers In Biotech: Kite Pharma Inc (KITE) And Eleven Biotherapeutics Inc (EBIO) -
07/11/16 08:32 AMEleven Biotherapeutics: What Went Wrong, What Went Right, And How You Can Spot Similar Opportunities In The Future
07/09/16 07:13 AMEleven Biotherapeutics Inc. Realized Volatility Hits Extreme Level - CML News
07/09/16 07:13 AMHome Biotech Stocks Eleven Biotherapeutics, Inc. | $EBIO Stock | Shares Spike Up On Positive... - TickerTV News (press release)
07/08/16 03:45 PMEleven Biotherapeutics Inc. (EBIO) Is Rising After Milestone Achieved
07/08/16 03:45 PMEleven Biotherapeutics Soars on Investigational Milestone
07/08/16 03:45 PMEleven Biotherapeutics (EBIO) Announces Effectiveness of IND Application for EBI-031; to Receive $22M Milestone Payment
07/08/16 03:45 PMEBIO Soars after First Milestone Payment in Drug Licensing Deal
07/08/16 03:45 PMBuzz Stocks: Eleven Biotherapeutics Inc, Juno Therapeutics Inc, and Mitel Networks Corporation
07/08/16 03:45 PMMovers And Shakers In Biotech: Kite Pharma Inc (NASDAQ:KITE) And Eleven Biotherapeutics Inc (NASDAQ:EBIO)
07/08/16 09:14 AMEleven Biotherapeutics (EBIO) Stock Skyrocketing on Eye Disease Treatment -
07/08/16 06:08 AMEleven Biotherapeutics' stock rockets after milestone payment announcement -
07/07/16 03:47 PMEleven Biotherapeutics (EBIO) Announces Effectiveness of IND Application for EBI-031; to Receive $22M Milestone ... - StreetInsider.com
07/07/16 03:39 PMELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
07/07/16 03:39 PMELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
07/07/16 03:31 PMEleven Biotherapeutics Announces Effectiveness of Investigational New Drug Application for EBI-031 - [at noodls] - 75d433fe-13d2-46d9-b0b5-63d3ec0e1c3d.pdf July 7, 2016 Eleven entitled to receive $22.5 million milestone payment for IND effectiveness CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: ...
07/07/16 03:31 PMEleven Biotherapeutics Announces Effectiveness of Investigational New Drug Application for EBI-031 - [at noodls] - 75d433fe-13d2-46d9-b0b5-63d3ec0e1c3d.pdf July 7, 2016 Eleven entitled to receive $22.5 million milestone payment for IND effectiveness CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: ...
07/07/16 07:26 AMEleven Biotherapeutics Inc (EBIO) Current Analyst Ratings - Fiscal Standard
07/06/16 08:28 AMHC Stocks News: CIGNA Corporation (NYSE:CI), Eleven Biotherapeutics Inc (NASDAQ:EBIO) - share market updates (press release)
07/06/16 08:28 AMHC Stocks in Top Row: Eleven Biotherapeutics Inc (NASDAQ:EBIO), EXACT Sciences Corporation (NASDAQ:EXAS) - share market updates (press release)
07/06/16 08:28 AMAnalyst Overview: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - News Oracle
07/06/16 08:28 AMEleven Biotherapeutics Inc. (EBIO) Jumps 14.89% on July 05 - Equities.com
07/05/16 03:38 PMEleven Biotherapeutics Incorporated (NASDAQ:EBIO) Short Interest Increased By 10.08% - Press Telegraph
07/01/16 08:49 PMEleven Biotherapeutics Inc. (EBIO) Drops 10.7% on June 30 - Equities.com
07/01/16 05:10 PMETF’s with exposure to Eleven Biotherapeutics, Inc. : July 1, 2016 -
06/28/16 03:42 PMAnalyst Recommended Stock: Eleven Biotherapeutics (EBIO) - News Oracle
06/26/16 08:44 AMEleven Biotherapeutics Incorporated (NASDAQ:EBIO) Sellers Increased By 10.08% Their Shorts - Engelwood Daily
06/23/16 02:41 PMEleven Biotherapeutics (EBIO) to Eliminate 14 Positions, 70% of Workforce - StreetInsider.com
06/22/16 03:28 PMELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Material Impairme -
06/20/16 01:22 PMETF’s with exposure to Eleven Biotherapeutics, Inc. : June 20, 2016 -
06/19/16 03:30 PMThis Weeks Broker Views For Eleven Biotherapeutics Inc (EBIO) - Fiscal Standard
06/18/16 08:17 AMEleven Biotherapeutics Inc. (EBIO) Jumps 15.25% on June 16 - Equities.com
06/16/16 08:59 PMEleven Biotherapeutics Inc(NASDAQ:EBIO): That’s How Our Premium Members Made A Quick 140% Profit
06/16/16 03:45 PMComprehensive Report on: Cerner Corporation (NASDAQ:CERN), Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Beacon Chronicle
06/15/16 03:48 PMShire PLC (ADR) (NASDAQ:SHPG) & Eleven Biotherapeutics (NASDAQ:EBIO) Healthcare Trend Analysis Report - Wall Street 24
06/15/16 03:48 PMEleven Biotherapeutics (EBIO) Showing Signs Of A Dead Cat Bounce Today - TheStreet.com
06/15/16 08:30 AMNotable Analysts Recommendation to Monitor: GlaxoSmithKline PLC (NYSE:GSK) , Eleven Biotherapeutics, Inc ... - Street Updates
06/15/16 08:30 AMComplete Analysis of: Juniper Networks, Inc. (NYSE:JNPR), Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Beacon Chronicle

Social

About Eleven Biotherapeutics

Eleven Biotherapeutics logoEleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye. The Company is conducting research and development programs directed at both diseases of the front of the eye, such as dry eye disease and allergic conjunctivitis, and diseases of the back of the eye, such as diabetic macular edema (DME) and uveitis. The Company's lead product candidate is EBI-005, a cure for dry eye disease and allergic conjunctivitis. Its preclinical product candidates include EBI-031, a cure for DME, and EBI-028, a cure for uveitis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EBIO
  • CUSIP:
Key Metrics:
  • Previous Close: $2.69
  • 50 Day Moving Average: $2.21
  • 200 Day Moving Average: $1.12
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $41.41M
  • Beta: 1.99
  • Current Year EPS Consensus Estimate: $-1.75 EPS
  • Next Year EPS Consensus Estimate: $-1.85 EPS
Additional Links:
Eleven Biotherapeutics (NASDAQ:EBIO) Chart for Sunday, July, 24, 2016